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Closing Gaps in Care Around the GlobeKim Allan Williams, SR, MD, FACC, ACC PresidentO ne of the most frequent and compellingquestions I have gotten as President-Electof the American College of Cardiology
(ACC) is: “What are you going to do as President?” It
is a logical question—of course people want to know
the direction the next leader is going to take.
As ACC leaders, we are very fortunate to inherit
the foundational work of past leaders. In my case,
my most recent predecessors have done great work
to expand the ACC’s digital strategy and develop
a 5-year strategic plan; ensure a continued focus
on educational funding and research; broaden the
ACC’s reach internationally and across the car-
diovascular care team; and guarantee a focus on
patient-centered care. During my time as President,
I hope to focus on increasing our ongoing effec-
tiveness as advocates for patient access to the best
cardiovascular care possible, regardless of age, race,
ethnicity, sex, income, or geography. Additionally, I
hope to focus on the transformation of care across
patient populations.
It is well known that cardiovascular disease is a
leading cause of death all over the world. In fact,
cardiovascular disease mortality is projected to in-
crease from 17.5 million in 2013 to 23.6 million in
2030 (1). So many of these deaths are preventable
through education and a focus on closing gaps in
care across populations.
Tobacco use, for example, is responsible for
6 million preventable deaths/year across the globe,
according to the Centers for Disease Control and
Prevention. This is expected to increase to 8 million
deaths annually by 2030 (2). The World Health
Organization (WHO) has set a global target to reduce
the prevalence of current tobaccos use in personsCardiology, Washington, DC.over the age of 15 by 30%. A 1-size-ﬁts-all approach
is not the answer to reaching this goal. However,
targeting those areas where the greatest disparities
in usage occurs just might. For example, tobacco
use is 5 times higher among males (37%) than fe-
males (5%), causing 12% of global deaths compared
to 7% in females. Looking beyond sex to geogra-
phy, smoking is most prevalent in the Western
Paciﬁc region, where nearly one-half of the male
population over the age of 15 years smokes. Com-
ing in close second and third, with nearly 40% of
males smoking, are the European region and the
Eastern Mediterranean (3). Targeted smoking edu-
cation campaigns directed at males in these areas
could go a long way toward meeting the global
target.
On a broader scale, efforts to ensure that people are
receiving the necessary drug therapy and counseling
to prevent heart attacks and strokes are another
area ripe for improvement. Indeed, <50% of low-
income countries have tests and procedures in place
to screen for cardiovascular risk factors like choles-
terol and diabetes. Nearly 25% of countries do not
have guidelines for management of cardiovascular
disease. The probability of dying from 1 of 4 main
noncommunicable diseases (NCDs) (the most preva-
lent being cardiovascular disease) between the ages
of 30 and 70 years is highest in Southeast Asia at
25%, followed closely behind by Africa and the
Eastern Mediterranean region at >20%. This is com-
pared with countries like Australia, Israel, Italy,
Japan, Republic of Korea, and Switzerland, where the
probability is <10% (3).
The WHO has set a global target of at least
50% of eligible people receiving drug therapy and
counseling to prevent heart attacks and strokes.
To do this, the WHO recommends an approach
that addresses total cardiovascular risk versus an
approach to make treatment decisions solely on
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total risk approach enables integrated management
of hypertension, diabetes and other CV risk factors
in primary care and targets available resources
at those persons most at risk,” the organization
states (3).
What will it take to get here? There have been
several recent clinical trials exploring the use of the
“polypill” as an option for preventing heart attacks
and strokes in people over age 55 years, but further
research into cost-effectiveness and other factors
is needed. Making drugs more affordable is needed,
regardless, particularly in low-income countries.
For example, >30 days wages are needed by the
lowest paid unskilled worker in the Democratic
Republic of the Congo to earn enough money to
purchase originator brand medication and a little
more than 10 days of wages for the lowest-priced
generic hypertension medication (3). Wider-spread
use of clinical data registries could also allow for
better estimations of all-cause deaths, the effect
of drugs and devices on treatment of cardiovascular
disease, improvements in prevention across coun-
tries, and more. Funding for such surveillance,
monitoring, and research is necessary, however,
particularly in the areas of Africa and the Eastern
Mediterranean.
Community-wide programs targeting cardiovascu-
lar disease risk reductions are also proving to be
successful. A study published early this year in the
Journal of the American Medical Association analyzed
data over 40 years from 22,444 rural, low-income
residents in Franklin County, Maine, beginning in
the 1970s. Residents were exposed to the Franklin
Cardiovascular Health Program, which emphasized
detection and control of hypertension and hyperlip-
idemia; minimal tobacco use; management of dia-
betes; and an active lifestyle and healthy eating.
Hospital staff as well as local businesses and schools
were actively involved in the program to ensure
continuity across the county. Results were impres-
sive, with control over hypertension increasing from
18% in 1975 to 43% in 1978, whereas control of
elevated cholesterol increased from 0.4% in 1986 to
29% in 2010. The rate of quitting smoking improved
from 49% in 1996 to 70% in 2000. Mortality rates
also decreased below Maine averages from 1970 to
2010 (4).
How can the ACC have an effect? With nearly
50,000 members around the globe; a growing net-
work of domestic and international chapters with
networks on the ground in countless states, coun-
tries, and provinces; and strong partnerships withother medical specialty societies and government
agencies, the College can have an effect that few
other medical societies can deliver. If we can work
together to increase international participation in
educational activities, encourage global use and ex-
change of data, and raise public awareness about
cardiovascular disease and its risk factors, progress
is well within our grasp.
Over the last several years, the ACC has also
actively advised the United Nations on its efforts to
combat NCDs since the 2011 Political Declaration of
the United Nations High-Level Meeting on NCDs. In
fact, ACC Past Presidents John Gordon Harold, MD,
MACC, Patrick T. O’Gara, MD, MACC, and William
Zoghbi, MD, MACC, have all played critical roles in
moving from discussion to action around the global
target of a 25% reduction in premature mortality
from NCDs by 2025. As a member of the NCD Alli-
ance, the ACC is working to support this global
target, as well as corresponding NCD targets focused
on high blood pressure, smoking cessation, dia-
betes, obesity, and reliable access to medicines.
These goals are embedded in the WHO’s global ac-
tion plan against NCDs. In addition to the WHO, we
share these goals with the American Heart Associ-
ation, European Society of Cardiology, World Heart
Association, American Medical Association, Associ-
ation of Black Cardiologists, and many other medi-
cal societies with whom we share goals and
strategies.
As technology becomes even more widespread, the
ACC can play an important role in advising on the use
of clinical registries to improve care, as well as the
development of clinical guidelines. Providing access
to educational resources is also an area of strength
for the College, particularly with the growth and use
of mobile devices. Online education and access to
guidelines and the latest research is literally within
one’s grasp.
Of course we will not solve all of the world’s
cardiovascular problems in 1 year, but I certainly
hope to continue us on the path to success and gain
more momentum during this year. I hope to build
upon our already solid foundation and move us
even closer to taking down heart disease as the
#1 killer worldwide. This goal is within our grasp
and we will succeed.
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